Lowell George H, Ziv Sagit, Bruzil Svetlana, Babecoff Ron, Ben-Yedidia Tamar
BiondVax Pharmaceuticals Ltd., 14 Einstein St., Ness Ziona 7414002, Israel.
BiondVax Pharmaceuticals Ltd., 14 Einstein St., Ness Ziona 7414002, Israel.
Vaccine. 2017 Feb 1;35(5):713-715. doi: 10.1016/j.vaccine.2016.12.063. Epub 2017 Jan 5.
We previously reported a 2011/12 study in elderly showing that immunization with the universal influenza vaccine candidate, M-001, three weeks before administering trivalent influenza vaccine (TIV) enhanced seroconversion of Hemagglutination Inhibition (HAI) antibodies against known influenza vaccine strains circulating at that time. We now report that those subjects primed with M-001 prior to TIV in 2011 also showed, in their 2011 sera, significantly more HAI antibodies with improved seroprotection and seroconversion against strain A/Switzerland/9715293/2013(H3N2-like) that caused the 2014/15 influenza epidemic and that wasn't known to circulate in 2011/12. These data indicate that M-001 can provide broadened enhanced immunity extending even to influenza strains destined to circulate in future years. The fact that M-001 stimulates T cell activation and is devoid of HA hypervariable epitopes indicates that such broadened HAI responses effected by M-001 priming is due to extensive T cell priming.
我们之前报道了一项2011/12年度针对老年人的研究,该研究表明,在接种三价流感疫苗(TIV)前三周,使用通用流感疫苗候选株M-001进行免疫接种可增强针对当时流行的已知流感疫苗株的血凝抑制(HAI)抗体的血清转化。我们现在报告,那些在2011年TIV之前用M-001进行预处理的受试者,在他们2011年的血清中,针对导致2014/15年度流感流行且在2011/12年度未知其流行的A/瑞士/9715293/2013(H3N2样)毒株,也显示出显著更多的HAI抗体,其血清保护和血清转化得到改善。这些数据表明,M-001可以提供更广泛的增强免疫力,甚至扩展到未来几年注定要流行的流感毒株。M-001刺激T细胞活化且缺乏HA高变表位这一事实表明,M-001预处理所产生的这种更广泛的HAI反应是由于广泛的T细胞预处理。